Protagonist Therapeutics PTGX
NASDAQ PTGX
$141.36 +0.39 (+0.28%)
As of: Sep 30, 2026 · 2:50 PM EDT

Protagonist Therapeutics (PTGX) EV to EBITDA (2024 - 2026)

Updated

Protagonist Therapeutics' (PTGX) EV to EBITDA stood at 119.31 in Q2 2026, up 3.7% from 115.10 a year earlier.

Analysis

Protagonist Therapeutics (PTGX) EV to EBITDA (2024 - 2026) Analysis & Trends

On a TTM basis, Protagonist Therapeutics' EV to EBITDA came in at 91.07 as of Jun 30, 2026, up 61.7% year-over-year; for FY2024, it came in at 7.64.

  • Quarterly EV to EBITDA has ranged from 7.64 in Q4 2024 to 178.34 in Q3 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Protagonist Therapeutics 9.12 Bn 9.12 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 119.31
Sep 30, 2025 178.34
Jun 30, 2025 115.10
Mar 31, 2025 86.28
Dec 31, 2024 7.64
Sep 30, 2024 14.73
Jun 30, 2024 9.61
Mar 31, 2024 9.17
API Access

Protagonist Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=PTGX&period=max&api_key=YOUR_API_KEY